Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma

Critical Reviews in Oncology/Hematology

Volumn 55, Issue 3, 2005, Pages 193-199

  Atzpodien, J ^a,b,c   Wandert, T ^c   Reitz, M ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Europaisches Institut fur Tumor Immunologie und Pravention   (Germany)

Author keywords

Elderly patients; Immunotherapy; Renal cell carcinoma

Indexed keywords

ALPHA2A INTERFERON; CYTOKINE; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 24044447211     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.03.001     Document Type: Review

References (15)

1. R. Yancik, and L.A.G. Ries Aging and cancer in America: demographic and epidemiologic perspectives Hematol Oncol Clin N Am 14 2000 17 23
2. L. Repetto, and L. Balducci A case for geriatric oncology Lancet Oncol 3 2002 289 297
3. A. Pinto, R. De Filippi, F. Frigeri, G. Corazzelli, and N. Normanno Aging and the hemopoietic system Crit Rev Oncol/Hematol 48S 2003 3 12
4. C.T. Kouroukis, G.P. Browman, R. Esmail, and R.M. Meyer Chemotherapy for older cancer patients with newly diagnosed, advanced stage, aggressive histology non-hodgkin lymphoma: a systematic review Ann Int Med 136 2002 144 152
5. J. Atzpodien, A. Korfer, and C.R. Franks Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies Lancet 335 1990 1509 1512
6. J. Atzpodien, H. Kirchner, and H.J. Illiger IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomised clinical trial Br J Cancer 85 8 2001 1130 1136
7. J. Atzpodien, H. Kirchner, and U. Jonas 13-cis-retinoic acid, IFN-alpha2a, IL-2 and chemotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) J Clin Oncol 22 7 2004 1188 1194
8. D.T. Sleijfer, R.A. Janssen, J. Buter, E.G. de Vries, P.H. Willemse, and N.H. Mulder Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis J Clin Oncol 10 7 1992 1119 1123
9. A. Schomburg, H. Kirchner, and J. Atzpodien Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens Acta Hematol 89 3 1993 119 131
10. A. Schomburg, H. Kirchner, and J. Atzpodien Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy J Cancer Res Clin Oncol 119 12 1993 745 755
11. A. Schomburg, H. Kirchner, and E. Lopez-Hanninen Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy Am J Clin Oncl 17 3 1994 199 209
12. J. Atzpodien, P. Royston, T. Wandert, and M. Reitz Metastatic renal carcinoma comprehensive prognostic system Br J Cancer 88 2003 348 353
13. I. Yusim, W. Mermershtain, E. Neulander, I. Eidelberg, I. Gusakova, and J. Kaneti Influence of age on the prognosis of patients with renal cell carcinoma (RCC) Onkologie 25 6 2002 548 550
14. L. Elias, M. Binder, and A. Mangalik Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma Am J Clin Oncol 22 2 1999 156 161
15. J.G. Doherty, A. Rufer, P. Bartholomew, and D.M. Beaumont The presentation, treatemnt and outcome of renal cell carcinoma in old age Age Ageing 28 4 1999 359 362